Drug intelligence / Profile preview

MAX-10

Development stage: Preclinical
Lead developer: Guangzhou Zaiji Medical Technology
Modality: Small Molecules
Administration: Transdermal

Overview

MAX-10 is a small molecule drug candidate currently in preclinical development by Maxinovel for the treatment of psoriasis. It is designed for transdermal administration, a route that aims to deliver therapeutic agents directly through the skin to provide localized treatment while potentially minimizing systemic side effects. As of the current pipeline status, the specific biological target and mechanism of action for MAX-10 have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on MAX-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAX-10.

Explore the full profile